4.6 Article

Collagen X Biomarker (CXM), Linear Growth, and Bone Development in a Vitamin D Intervention Study in Infants

Journal

JOURNAL OF BONE AND MINERAL RESEARCH
Volume 37, Issue 9, Pages 1653-1664

Publisher

WILEY
DOI: 10.1002/jbmr.4650

Keywords

COLLAGEN X BIOMARKER; LINEAR GROWTH; BONE; VITAMIN D; EARLY CHILDHOOD

Funding

  1. Sigrid Juselius Foundation
  2. Novo Nordisk Foundation
  3. Folkhalsan Research Foundation
  4. Academy of Finland
  5. Foundation for Pediatric Research
  6. Special Governmental Subsidy for Clinical Research
  7. Finska Lakaresallskapet
  8. Paivikki and Sakari Sohlberg the Foundation
  9. Juho Vainio Foundation
  10. Finnish Medical Foundation

Ask authors/readers for more resources

This study examines the relationship between Collagen X biomarker (CXM) and linear growth rate and bone development, as well as the modifying effects of vitamin D supplementation. The findings suggest that CXM is related to linear growth velocity during the second year of life but not to bone development. Furthermore, higher CXM levels in infants receiving higher vitamin D supplementation are associated with an accelerated growth rate in length.
Collagen X biomarker (CXM) is suggested to be a biomarker of linear growth velocity. However, early childhood data are limited. This study examines the relationship of CXM to the linear growth rate and bone development, including the possible modifying effects of vitamin D supplementation. We analyzed a cohort of 276 term-born children participating in the Vitamin D Intervention in Infants (VIDI) study. Infants received 10 mu g/d (group-10) or 30 mu g/d (group-30) vitamin D-3 supplementation for the first 2 years of life. CXM and length were measured at 12 and 24 months of age. Tibial bone mineral content (BMC), volumetric bone mineral density (vBMD), cross-sectional area (CSA), polar moment of inertia (PMI), and periosteal circumference (PsC) were measured using peripheral quantitative computed tomography (pQCT) at 12 and 24 months. We calculated linear growth as length velocity (cm/year) and the growth rate in length (SD unit). The mean (SD) CXM values were 40.2 (17.4) ng/mL at 12 months and 38.1 (12.0) ng/mL at 24 months of age (p = 0.12). CXM associated with linear growth during the 2-year follow-up (p = 0.041) but not with bone (p = 0.53). Infants in group-30 in the highest tertile of CXM exhibited an accelerated mean growth rate in length compared with the intermediate tertile (mean difference [95% CI] -0.50 [-0.98, -0.01] SD unit, p = 0.044) but not in the group-10 (p = 0.062) at 12 months. Linear association of CXM and growth rate until 12 months was weak, but at 24 months CXM associated with both length velocity (B for 1 increment of root CXM [95% CI] 0.32 [0.12, 0.52] cm/yr, p = 0.002) and growth rate in length (0.20 [0.08, 0.32] SD unit, p = 0.002). To conclude, CXM may not reliably reflect linear growth from birth to 12 months of age, but its correlation with growth velocity improves during the second year of life. (c) 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available